CROSSJECT
Pre-clinicalCrossject is revolutionizing the administration of well-established treatments with its needle-free auto-injector ZENEO®.
Founded
1996
Focus
Drug Delivery
About
Crossject is revolutionizing the administration of well-established treatments with its needle-free auto-injector ZENEO®.
Funding History
2Total raised: $15.3M
Grant$2.8MEuropean Innovation CouncilNov 15, 2022
Series B$12.5MUndisclosedMay 15, 2021
Company Info
TypePrivate
Founded1996
LocationDijon, France
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile